Next Generation Cancer Vaccines-Make It Personal!
Loading...
Embargo End Date
ICR Authors
Authors
Terbuch, A
Lopez, J
Lopez, J
Document Type
Journal Article
Date
2018-08-09
Date Accepted
2018-08-07
Abstract
Dramatic success in cancer immunotherapy has been achieved over the last decade with the introduction of checkpoint inhibitors, leading to response rates higher than with chemotherapy in certain cancer types. These responses are often restricted to cancers that have a high mutational burden and show pre-existing T-cell infiltrates. Despite extensive efforts, therapeutic vaccines have been mostly unsuccessful in the clinic. With the introduction of next generation sequencing, the identification of individual mutations is possible, enabling the production of personalized cancer vaccines. Combining immune check point inhibitors to overcome the immunosuppressive microenvironment and personalized cancer vaccines for directing the host immune system against the chosen antigens might be a promising treatment strategy.
Citation
Vaccines, 2018, 6 (3)
Source Title
Publisher
MDPI
ISSN
2076-393X
eISSN
2076-393X
Collections
Research Team
Medicine (de Bono Prostate)